How did the IRA Part D redesign change MS formulary coverage?

New research highlighted by Drug Channels found that Medicare Part D plans shifted in 2025 to near-universal generic coverage for multiple sclerosis drugs after years of favoring high-list, high-rebate brands. The article ties that reversal to the IRA redesign, which increased plan liability and removed the 5% beneficiary coinsurance, changing formulary incentives.